Home  »  Business   »  Is BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) St...

Is BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Still A Hot Buy?

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) traded at $12.70 at close of the session on Tuesday, 11/22/22, made an upward move of 1.68% on its previous day’s price.

Looking at the stock we see that its previous close was $12.49 and the beta (5Y monthly) reads 1.99 with the day’s price range being $12.225 – $12.71. In terms of its 52-week price range, BCRX has a high of $19.99 and a low of $7.61. The company’s stock has lost about -7.84% over that past 30 days.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


BioCryst Pharmaceuticals Inc. has a market cap of $2.33 billion and is expected to release its quarterly earnings report on Feb 21, 2023 – Feb 27, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.16, with the EPS growth for the year raised at -$1.11 for 2022 and -$0.8 for next year. These figures represent -7.80% and 27.90% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $77 million, with a low of $72.58 million and a high of $91.21 million. The median projection represents growth squeezing down to 63.30% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $268.45 million, or 70.80% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the BCRX stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of Hold.

Based on estimates by 12 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 6 have rated the BioCryst Pharmaceuticals Inc. (BCRX) stock as a Hold, while 6 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -0.66% off its SMA20 and -3.20% from its 50-day simple moving average. The RSI (14) is pointing at 48.14 while the volatility over the past week is 4.06% and jumps to 5.34% over the past one month. The beta value is 1.98, while the average true range (ATR) is currently pointing at 0.71. The average price target for the stock over the next 12 months is $17.60, with the estimates having a low of $12.00 and a high of $30.00. These price ends are 5.51% and -136.22% off the current price level respectively, although investors could be excited at the prospect of a -22.05% if the BCRX share price touches on the median price of $15.50.

Let’s briefly compare BioCryst Pharmaceuticals Inc. (BCRX) stock to its peers. We find that current price change of 1.68% and 2.01% over the past 12 months for BCRX competes that of CEL-SCI Corporation (CVM), which has seen its stock price rise 4.26% in the last trading session and was -71.57% over the last one year. Another of its peers Emergent BioSolutions Inc. (EBS) has gained 1.77% previous session, and was -69.78% down over the past year, while Sarepta Therapeutics Inc. (SRPT) was also up 1.29% in the last session, while its price remained in the green at 42.94% over the same period. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.36% and 1.18%, respectively, at close of the trading.

Coming back to BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), we note that the average 3-month trading volume was 2.62 million, while that of the preceding 10-day period stands at 2.45 million. Current shares outstanding are 186.18 million.

The insiders hold 0.20% of the company’s shares while institutions hold 81.20%. The data shows that short shares as of Oct 30, 2022, stood at 27.63 million at a short ratio of 10.76. This represents a 14.82% short interest in shares outstanding on Oct 30, 2022. Shares short fall in October from the previous month at 28.13 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -8.30% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *